Viral Elimination Reduces Incidence of Malignant Lymphoma in Patients with Hepatitis C - 09/08/11
, Kenji Ikeda, MD, Yasuji Arase, MD, Hiromi Yatsuji, MD, Hitomi Sezaki, MD, Tetsuya Hosaka, MD, Norio Akuta, MD, Masahiro Kobayashi, MD, Fumitaka Suzuki, MD, Yoshiyuki Suzuki, MD, Hiromitsu Kumada, MD
Requests for reprints should be addressed to Yusuke Kawamura, MD, Department of Hepatology, Toranomon Hospital 2-2-2, Toranomon, Minato-ku, Tokyo 105-8470, Japan.Abstract |
Purpose |
A high prevalence of malignant lymphoma among patients with hepatitis C virus (HCV) infection has been reported. The aim of this retrospective study was to determine the incidence of malignant lymphoma and the relationship between malignant lymphoma and viral elimination in patients with HCV.
Method |
We studied 501 consecutive HCV-infected patients who had never received interferon therapy and 2708 consecutive HCV-infected patients who received interferon therapy.
Results |
In the non-interferon group, the cumulative rates of malignant lymphoma development were 0.6% at the 5th year, 2.3% at the 10th year, and 2.6% at the 15th year. The cumulative rates of malignant lymphoma development in interferon-treated patients with sustained virologic response were 0% at the 5th year, 0% at the 10th year, and 0% at the 15th year. The cumulative rates of malignant lymphoma development with persistent infection were 0.4% at the 5th year, 1.5% at the 10th year, and 2.6% at the 15th year. The malignant lymphoma development rate was higher in patients with persistent infection than in patients with sustained virologic response (P=.0159). The hazard ratio of lymphomagenesis in 1048 patients with sustained virologic response was significantly lower than in patients with persistent infection (hazard ratio: 0.13; P=.049).
Conclusion |
Our retrospective study is the first to determine the annual incidence of malignant lymphoma among patients with HCV at 0.23%. Our results indicate that sustained virologic response induced by interferon therapy protects against the development of malignant lymphoma in patients with chronic HCV.
Le texte complet de cet article est disponible en PDF.Keywords : Cohort study, Hepatitis C virus, Hepatocellular carcinoma, Interferon, Malignant lymphoma, Sustained virologic response, Viral elimination\
Plan
| The present work was supported in part by Grants-in-Aid from Okinaka Memorial Institute for Medical Research and the Japanese Ministry of Health, Labour and Welfare. |
Vol 120 - N° 12
P. 1034-1041 - décembre 2007 Retour au numéro
Article précédent
- A Cut Above
- Elisabeth B. Marsh, Grant V. Chow, Gary X. Gong, Darius A. Rastegar, Emmanuel S. Antonarakis
- Skin Temperature Monitoring Reduces the Risk for Diabetic Foot Ulceration in High-risk Patients
- David G. Armstrong, Katherine Holtz-Neiderer, Christopher Wendel, M. Jane Mohler, Heather R. Kimbriel, Lawrence A. Lavery
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?